Development of Asolectin-Based Liposomal Formulation for Controlled and Targeted Delivery of Erlotinib as a Model Drug for EGFR Monotherapy

Investigators developed the liposomal formulation, by ether injection method, comprising erlotinib, a tyrosine kinase EGFR inhibitor, proposed to be targeted through enhanced permeability and retention effect effect against pancreatic cancer.